<DOC>
	<DOCNO>NCT00075699</DOCNO>
	<brief_summary>RATIONALE : Active symptom control may decrease chest pain , breathlessness , sweating , general discomfort patient malignant pleural mesothelioma . It yet know active symptom control effective without chemotherapy . PURPOSE : This randomized phase III trial study active symptom control chemotherapy see well work compare active symptom control alone treat patient malignant pleural mesothelioma .</brief_summary>
	<brief_title>Active Symptom Control With Without Chemotherapy Treating Patients With Malignant Pleural Mesothelioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival patient malignant pleural mesothelioma treat active symptom control ( ASC ) alone vs ASC mitomycin , vinblastine , cisplatin v ASC vinorelbine . Secondary - Compare toxic effect regimens patient . - Compare symptom palliation ( chest pain , breathlessness , malaise , sweat attack ) patient treat regimen . - Compare performance status patient treat regimen . - Compare analgesic usage patient treat regimen . - Compare tumor response progression-free survival patient treat regimen . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize 1 3 treatment arm . - Arm I : Patients receive active symptom control ( ASC ) regular visit specialist clinic . ASC may include steroid , analgesic , appetite stimulant , bronchodilator , and/or palliative radiotherapy , require . - Arm II : Patients receive ASC chemotherapy comprise mitomycin IV , vincristine IV , cisplatin IV day 1 . Chemotherapy repeat every 21 day total 4 course . - Arm III : Patients receive ASC vinorelbine IV 5 minute weekly 6 week . Vinorelbine repeat every 55 day total 2 course . Quality life assess baseline , every 3 week 21 week , every 8 week thereafter . Patients follow 15 , 18 , 21 week , every 8 week thereafter . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 840 patient ( 280 per treatment arm ) accrue study within 4 year .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically immunohistochemically confirm malignant pleural mesothelioma Epithelial histological type allow No 3 month since diagnosis Symptomatic pleural effusion must treat bring control drainage , pleurodesis , pleurectomy Prior surgical resection mesothelioma allow provide 2 CT scan least 6 week apart show stable progressive disease PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy Not specify Hematopoietic WBC &gt; 3,000/mm^3 Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic Not specify Renal Creatinine clearance &gt; 50 mL/min Pulmonary See Disease Characteristics Other Not pregnant nursing Fertile patient must use effective contraception Considered medically fit receive chemotherapy No disease prior malignancy likely interfere protocol treatment comparisons No clinical evidence infection PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy mesothelioma Endocrine therapy Not specify Radiotherapy Prior local radiotherapy wound site exploratory thoracotomy allow Surgery See Disease Characteristics See Radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>epithelial mesothelioma</keyword>
	<keyword>localize malignant mesothelioma</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
</DOC>